Teceleukin
Also known as: Aldesleukin, Proleukin, recombinant IL-2 (Roche), Recombinant IL‑2, rIL-2 (teceleukin), Ro 23-6019, ro-23-6019, Teceleukin
Source Teceleukin at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Recombinant human interleukin‑2 (rhIL‑2) used as immunotherapy for metastatic renal cell carcinoma and metastatic melanoma; stimulates immune effector cells.
Mechanism of Action
Binds IL-2 receptor (CD25/CD122/CD132) activating JAK/STAT pathway, promoting T‑cell proliferation and NK cell activation
Routes of Administration
Goals & Uses
- NK cell and T cell expansionImmunologyModerate
- Metastatic melanomaOncologyHigh
- Metastatic renal cell carcinomaOncologyHigh
- HIV/AIDS immune reconstitutionInfectious Disease / ImmunologyLow
- Antitumor immunotherapyOncologyLow
Contraindications
- Organ transplant recipientsImmunologyHigh
- Severe hypersensitivity to IL‑2AllergyHigh
- Active uncontrolled infectionInfectious DiseaseModerate
- Autoimmune disease (active)ImmunologicalHigh
- Organ transplant recipients on immunosuppressionTransplantHigh
- Severe cardiac dysfunctionCardiovascularHigh
Adverse Effects
- Capillary leak syndromeVascularCommonLeakage of fluid from blood vessels into tissues
- ThrombocytopeniaHematologicUncommonLow platelet count
- HypotensionCardiovascularCommonLow blood pressure
- Neurotoxicity / mental status changesNeurologicalUncommon
- Nausea/vomitingGastrointestinalCommon
- Renal dysfunctionRenalUncommon
- Fever and chillsConstitutionalCommon
- Fever/chillsConstitutionalCommon
- Nausea and vomitingGastrointestinalCommon
Drug Interactions
- High‑dose corticosteroidsModerate
- Antihypertensive agentsModerate
- CyclosporineModerate
- Nephrotoxic agentsModerate
- CorticosteroidsModerate
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Pregnant or breastfeeding womenReproductiveRelative
- BreastfeedingReproductiveRelative
- Patients with renal or hepatic impairmentOrgan FunctionRelative
Regulatory Status
- European UnionApprovedApproved: metastatic renal cell carcinoma, metastatic melanomaApproved under similar trade names
- JPApprovedApproved: renal cell carcinoma, melanomaMarketed as Teceleukin
- United StatesApprovedApproved: metastatic renal cell carcinoma, metastatic melanomaMarketed as Aldesleukin (Proleukin)
- United KingdomUnapprovedNo regulatory approval in the UK.
Approved in the US (as aldesleukin/Proleukin) in 1992; marketed as Teceleukin in Japan and other regions.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Teceleukin?
Recombinant human interleukin‑2 (rhIL‑2) used as immunotherapy for metastatic renal cell carcinoma and metastatic melanoma; stimulates immune effector cells.
What is Teceleukin used for?
Teceleukin is educationally associated with: NK cell and T cell expansion, Metastatic melanoma, Metastatic renal cell carcinoma, HIV/AIDS immune reconstitution, Antitumor immunotherapy. Educational only — not medical advice.
How is Teceleukin administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of Teceleukin?
Reported adverse effects include: Capillary leak syndrome, Thrombocytopenia, Hypotension, Neurotoxicity / mental status changes, Nausea/vomiting, Renal dysfunction, Fever and chills, Fever/chills, Nausea and vomiting. This list is not exhaustive — consult a qualified clinician.
Who should avoid Teceleukin?
Recorded contraindications: Organ transplant recipients, Severe hypersensitivity to IL‑2, Active uncontrolled infection, Autoimmune disease (active), Organ transplant recipients on immunosuppression, Severe cardiac dysfunction. Consult a qualified clinician before use.